Navigation Links
Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
Date:2/3/2009

QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), announced today that its Neurobionix division has obtained CE Mark approval for its Neurostep(TM) System, the first ever approval for a closed-loop system (CLS) used on peripheral nerves. CE Mark represents regulatory approval needed for the sale of the Neurostep(TM) in any of the Member States of the European Union.

The Neurostep(TM), a fully implantable investigational neuromodulation product designed to treat gait disorders (e.g., foot drop), is the first CLS product aimed at using the patient's own nervous system as the source for detection of intention to move and control their leg. Contrary to other systems that use surrogates such as external sensors, the Neurostep(TM) detects intrinsic muscle activities and surface sensation events from the nerve signals delivered to the spine and brain. This information is then used as the trigger for intervention through neurostimulation, as needed, to complete function. We believe that patients implanted with the Neurostep(TM) will experience remedy to their foot drop and an improved walking pattern that should contribute to give them more independent mobility and a healthier lifestyle.

CE Mark approval gives the Neurobionix division the ability to train and educate physicians in preparation for market release of the Neurostep(TM) System, which is planned for late 2009 in the European Union. The clearance to enter the European market allows the Neurobionix division to increase its market development activity by identification and education of hospitals and physicians that would introduce this new solution to patients in the most expedient manner.

"The approval of the Neurostep(TM) System marks a major milestone in the repositioning of the Neurobionix division into a full function organization that can develop and deliver products of a distinctive value for the market", said Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division. He further said, "We feel confident that we can build on this success to enable commercial launch of the Neurostep(TM) System in the European market in 2009".

While the Neurostep(TM) System is not currently available in the United States, Victhom is planning to engage with the U.S. Food and Drug Administration (FDA) to pursue plans for bringing this new solution for foot drop therapy to patients in the United States.

"Accomplishing CE Mark approval is the latest step in what continues to be the steady advance toward commercialization of the Neurostep(TM)", said Mr. Normand Rivard, Acting President of the Company. "These recent accomplishments are an indication of our commitment to this business and the ability of the Company to deliver on its scientific and business objectives", he added.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
2. Victhom to Participate in the OneMedPlace Finance Forum
3. Victhom Announces Launch of Enhanced Company Website
4. Victhom announces the completion of the second phase of the apnea therapy development
5. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
6. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
7. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
10. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017  Kingfisher Talent, ... search and leadership development, and Virdis Group, global executive search ... exclusive alliance that enables clients to leverage the expertise and ... "For our clients here in the Boston ... diverse population of leadership talent throughout the US, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is pleased to ... and scientific instruments. This year’s symposium, organized by the Pittcon 2018 program chair, ... Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high throughput IMS-MS ...
(Date:8/15/2017)... Linda, Ca (PRWEB) , ... August 15, 2017 ... ... coffee production and is threatened by various biotic and abiotic factors. During this ... complex evolutionary history of coffee, as well as gain a better understanding of ...
(Date:8/14/2017)... ... 14, 2017 , ... The Conference Forum has confirmed the one-day ... on September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning ... and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
Breaking Biology News(10 mins):